CL2008000479A1 - Peptido de glucagon no nativo; composicion farmaceutica que lo comprende; y metodo para tratar la hipoglucemia y diabetes. - Google Patents

Peptido de glucagon no nativo; composicion farmaceutica que lo comprende; y metodo para tratar la hipoglucemia y diabetes.

Info

Publication number: CL2008000479A1
Authority: CL; Chile
Prior art keywords: hipoglucemia; understands; diabetes; peptide; treat
Prior art date: 2007-02-15

Application number

CL2008000479A

Other languages

English (en)

Inventor

Day James Patterson J Jonathan

Original Assignee

Indiana Uniersity Res And Tech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-15

Filing date

2008-02-14

Publication date

2008-08-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-14 Application filed by Indiana Uniersity Res And Tech filed Critical Indiana Uniersity Res And Tech

2008-08-22 Publication of CL2008000479A1 publication Critical patent/CL2008000479A1/es

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CL2008000479A 2007-02-15 2008-02-14 Peptido de glucagon no nativo; composicion farmaceutica que lo comprende; y metodo para tratar la hipoglucemia y diabetes. CL2008000479A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89008707P	2007-02-15	2007-02-15
US93856507P	2007-05-17	2007-05-17

Publications (1)

Publication Number	Publication Date
CL2008000479A1 true CL2008000479A1 (es)	2008-08-22

Family

ID=39690775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2008000479A CL2008000479A1 (es)	2007-02-15	2008-02-14	Peptido de glucagon no nativo; composicion farmaceutica que lo comprende; y metodo para tratar la hipoglucemia y diabetes.

Country Status (28)

Country	Link
US (3)	US8454971B2 (es)
EP (2)	EP2111414B1 (es)
JP (2)	JP6017754B2 (es)
KR (2)	KR20090119876A (es)
CN (1)	CN101790538B (es)
AR (2)	AR065349A1 (es)
AU (1)	AU2008216265B2 (es)
BR (1)	BRPI0807728A2 (es)
CA (1)	CA2677932A1 (es)
CL (1)	CL2008000479A1 (es)
CR (1)	CR11028A (es)
DO (1)	DOP2009000194A (es)
EA (1)	EA017849B1 (es)
EC (1)	ECSP099622A (es)
GE (1)	GEP20135944B (es)
GT (1)	GT200900229A (es)
HN (1)	HN2009001593A (es)
IL (1)	IL200396A (es)
MA (1)	MA31242B1 (es)
MX (1)	MX2009008241A (es)
NI (1)	NI200900158A (es)
NZ (1)	NZ578948A (es)
PA (1)	PA8769301A1 (es)
PE (2)	PE20090108A1 (es)
TN (1)	TN2009000313A1 (es)
TW (1)	TWI547499B (es)
WO (1)	WO2008101017A2 (es)
ZA (1)	ZA200905521B (es)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP1894591B1 (en)	2002-03-20	2013-06-26	MannKind Corporation	Cartridge for an inhalation apparatus
EP1786784B1 (en)	2004-08-20	2010-10-27	MannKind Corporation	Catalysis of diketopiperazine synthesis
DK2314298T3 (en)	2004-08-23	2015-06-15	Mannkind Corp	Microparticles comprising diketopiperazinsalte for drug delivery
BRPI0616071B8 (pt)	2005-09-14	2021-05-25	Mannkind Corp	métodos de revestir uma micropartícula cristalina pré-formada em suspensão com um agente ativo
EP1959986B1 (en) *	2005-11-07	2014-07-23	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
IN2015DN00888A (es)	2006-02-22	2015-07-10	Mannkind Corp
WO2008086086A2 (en)	2007-01-05	2008-07-17	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2111414B1 (en)	2007-02-15	2014-07-02	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
JP5385266B2 (ja)	2007-06-15	2014-01-08	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
EP2211842B1 (en) *	2007-10-24	2015-08-12	MannKind Corporation	An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
JP5771005B2 (ja) *	2007-10-30	2015-08-26	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
MX2010004297A (es) *	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Antagonistas de glucagon.
EP2249853A4 (en) *	2008-01-30	2012-12-26	Univ Indiana Res & Tech Corp	ESTER BASED PEPTIDE PRODRUGS
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
TWI592178B (zh)	2008-06-13	2017-07-21	曼凱公司	用於藥物傳輸之乾粉吸入器及系統
AU2013205144B2 (en) *	2008-06-17	2015-07-16	Indiana University Research And Technology Corporation	GIP-based mixed agonists for treatment of metabolic disorders and obesity
AU2009274425B2 (en)	2008-06-17	2014-05-15	Indiana University Research And Technology Corporation	GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN104447980A (zh) *	2008-06-17	2015-03-25	印第安纳大学研究及科技有限公司	在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
CA2728284C (en) *	2008-06-17	2019-09-10	Richard D. Dimarchi	Glucagon/glp-1 receptor co-agonists
MX2010014240A (es)	2008-06-20	2011-03-25	Mankind Corp	Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
US8642540B2 (en)	2008-12-15	2014-02-04	Zealand Pharma A/S	Glucagon analogues
BRPI0823377A2 (pt) *	2008-12-15	2016-09-27	Zealand Pharma As	análogos de glucagon
US8642541B2 (en) *	2008-12-15	2014-02-04	Zealand Pharma A/S	Glucagon analogues
WO2010070251A1 (en) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2010080605A1 (en) *	2008-12-19	2010-07-15	Indiana University Research And Technology Corporation	Dipeptide linked medicinal agents
TWI489992B (zh) *	2008-12-19	2015-07-01	印地安那大學研究及技術公司	醯胺系胰高血糖素超級家族之胜肽前驅藥物
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
WO2010096052A1 (en) *	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
EP2405963B1 (en)	2009-03-11	2013-11-06	MannKind Corporation	Apparatus, system and method for measuring resistance of an inhaler
TWI547487B (zh)	2009-06-12	2016-09-01	曼凱公司	具限定比表面積之二酮基哌微粒子
CN102459325B (zh)	2009-06-16	2015-03-25	印第安纳大学科技研究有限公司	胃抑胜肽受体活化的胰高血糖素化合物
WO2011006497A1 (en) *	2009-07-13	2011-01-20	Zealand Pharma A/S	Acylated glucagon analogues
CN101993485B (zh) *	2009-08-20	2013-04-17	重庆富进生物医药有限公司	促胰岛素分泌肽类似物同源二聚体及其用途
IN2012DN00721A (es)	2009-09-02	2015-06-19	Merck Sharp & Dohme
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Axentomodulin polypeptide
US20130157953A1 (en) *	2010-01-20	2013-06-20	Zealand Pharma A/S	Treatment of cardiac conditions
CA2788304A1 (en) *	2010-01-27	2011-08-04	Indiana University Research And Technology Corporation	Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US8853212B2 (en)	2010-02-22	2014-10-07	Merck Sharp & Dohme Corp	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130053310A1 (en)	2010-03-26	2013-02-28	Novo Nordisk A/S	Novel glucagon analogues
US20130035285A1 (en)	2010-03-26	2013-02-07	Novo Nordisk A/S	Novel glucagon analogues
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2011134471A1 (en)	2010-04-27	2011-11-03	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
RU2604067C2 (ru)	2010-05-13	2016-12-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
WO2011146358A1 (en)	2010-05-21	2011-11-24	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
RU2571331C1 (ru)	2010-06-21	2015-12-20	Маннкайнд Корпорейшн	Системы и способы доставки сухих порошковых лекарств
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
EP2588126A4 (en)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
CN103068841A (zh)	2010-06-24	2013-04-24	西兰制药公司	胰高血糖素类似物
EP2585102B1 (en)	2010-06-24	2015-05-06	Indiana University Research and Technology Corporation	Amide-based insulin prodrugs
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN101974077A (zh) *	2010-09-15	2011-02-16	南京瑞年天平医药科技有限公司	一种新颖的多肽化合物
CA2816114C (en)	2010-11-03	2019-02-12	Jan Jezek	Novel composition comprising glucagon
CA2821766A1 (en)	2010-12-22	2012-06-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity
JP2014504597A (ja)	2011-01-20	2014-02-24	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体とインスリン類似体の組合せ物
JP2014510739A (ja)	2011-03-28	2014-05-01	ノヴォノルディスクアー／エス	新規のグルカゴン類似体
US8925726B2 (en)	2011-04-01	2015-01-06	Mannkind Corporation	Blister package for pharmaceutical cartridges
WO2012150503A2 (en)	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en)	2011-05-10	2012-11-15	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
EP2709645B1 (en)	2011-05-18	2023-08-09	Eumederis Pharmaceuticals, Inc.	Improved peptide pharmaceuticals
CA3064214C (en) *	2011-06-10	2023-03-07	Hanmi Science Co., Ltd.	Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
MX353402B (es)	2011-06-17	2018-01-11	Hanmi Science Co Ltd	Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo.
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
CN103857408B (zh)	2011-06-22	2017-04-12	印第安那大学科技研究公司	胰高血糖素/glp‑1受体协同激动剂
EP2723766A4 (en) *	2011-06-22	2015-05-20	Univ Indiana Res & Tech Corp	COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
US9944687B2 (en)	2011-07-04	2018-04-17	Imperial Innovations Limited	Compounds and their effects on feeding behaviour
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AR088161A1 (es)	2011-09-23	2014-05-14	Novo Nordisk As	Analogos de glucagon
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6018640B2 (ja)	2011-10-24	2016-11-02	マンカインドコーポレイション	疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
AR088636A1 (es)	2011-11-03	2014-06-25	Zealand Pharma As	Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina
CN103087174B (zh) *	2011-11-03	2015-11-18	华东师范大学	一种glp-1衍生物dlg3312及其固相化学合成方法
EP2780031B1 (en)	2011-11-17	2018-03-07	Indiana University Research and Technology Corporation	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
MX2014007120A (es)	2011-12-23	2015-03-05	Boehringer Ingelheim Int	Analogos de glucagon.
WO2013098408A1 (en)	2011-12-30	2013-07-04	Zealand Pharma A/S	Glucagon and cck receptor agonist peptide conjugates
IN2014DN09640A (es)	2012-04-16	2015-07-31	Kaneq Pharma Inc
NZ702333A (en)	2012-05-03	2017-06-30	Zealand Pharma As	Gip-glp-1 dual agonist compounds and methods
WO2013170636A1 (zh)	2012-05-18	2013-11-21	爱德迪安（北京）生物技术有限公司	用于糖尿病治疗的蛋白、蛋白缀合物及其应用
IN2014KN02830A (es)	2012-06-14	2015-05-08	Sanofi Sa
KR20150023013A (ko) *	2012-06-21	2015-03-04	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	수용체 활성을 나타내는 글루카곤 유사체
AU2013277372B2 (en)	2012-06-21	2018-03-29	Indiana University Research And Technology Corporation	Analogs of glucagon exhibiting GIP receptor activity
ES2624294T3 (es)	2012-07-12	2017-07-13	Mannkind Corporation	Sistemas de suministro de fármacos en polvo seco
SG11201500375PA (en)	2012-07-23	2015-02-27	Zealand Pharma As	Glucagon analogues
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20150297573A1 (en)	2012-10-24	2015-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
EP2911690A1 (en)	2012-10-26	2015-09-02	MannKind Corporation	Inhalable influenza vaccine compositions and methods
EP2915817B1 (en) *	2012-10-31	2018-06-20	Hybio Pharmaceutical Co., Ltd.	Method for preparing exenatide
SG10201602801YA (en)	2012-11-06	2016-05-30	Hanmi Pharm Ind Co Ltd	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR102213907B1 (ko)	2012-11-20	2021-02-09	메더리스 다이어비티즈, 엘엘씨	인슐린 저항성에 대한 개선된 펩티드 약제
WO2014081849A1 (en)	2012-11-20	2014-05-30	Phasebio Pharmaceuticals, Inc.	Formulations of active agents for sustained release
US10005817B2 (en)	2012-11-20	2018-06-26	Eumederis Pharmaceuticals, Inc.	Peptide pharmaceuticals
EP2935318A1 (en) *	2012-12-19	2015-10-28	Novo Nordisk A/S	Novel glp-1 receptor agonists with cholesterol efflux activity
CA2895875A1 (en)	2012-12-21	2014-06-26	Sanofi	Exendin-4 derivatives
RU2678134C2 (ru)	2013-03-14	2019-01-23	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Конъюгаты инсулин-инкретин
KR102246914B1 (ko)	2013-03-15	2021-04-30	맨카인드 코포레이션	미세결정성 디케토피페라진 조성물 및 방법
EP2968443B1 (en)	2013-03-15	2021-09-29	Protagonist Therapeutics, Inc.	Hepcidin analogues and uses thereof
DK2976325T3 (en)	2013-03-21	2017-06-06	Sanofi Aventis Deutschland	SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
CN105189465B (zh)	2013-03-21	2019-02-26	赛诺菲-安万特德国有限公司	合成含有乙内酰脲的肽产物
WO2014161835A1 (en)	2013-04-03	2014-10-09	Sanofi	Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
WO2014170496A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
WO2015021064A1 (en)	2013-08-05	2015-02-12	Mannkind Corporation	Insufflation apparatus and methods
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
WO2015055801A1 (en)	2013-10-17	2015-04-23	Zealand Pharma A/S	Acylated glucagon analogues
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
EA035688B1 (ru)	2013-11-06	2020-07-27	Зилэнд Фарма А/С	Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
WO2015081891A1 (en)	2013-12-06	2015-06-11	Baikang (Suzhou) Co., Ltd	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
EP3080155A1 (en)	2013-12-13	2016-10-19	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
MX2016010599A (es)	2014-02-18	2016-11-18	Novo Nordisk As	Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
RS62392B1 (sr)	2014-05-16	2021-10-29	Protagonist Therapeutics Inc	Tioetar peptidni antagonisti alfa4beta7 integrina
US9856306B2 (en)	2014-05-28	2018-01-02	Spitfire Pharma, Inc.	Peptide pharmaceuticals for insulin resistance
EP3151852A1 (en)	2014-06-04	2017-04-12	Novo Nordisk A/S	Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
JP5912150B2 (ja) *	2014-07-04	2016-04-27	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP6018129B2 (ja) *	2014-07-04	2016-11-02	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP5912151B2 (ja) *	2014-07-04	2016-04-27	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP6006264B2 (ja) *	2014-07-16	2016-10-12	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
SG10201810154WA (en)	2014-07-17	2018-12-28	Protagonist Therapeutics Inc	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CN104558198A (zh) *	2014-07-25	2015-04-29	成都贝爱特生物科技有限公司	GLP-1类似物和amylin类似物的融合蛋白制备及其用途
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
ES2822994T3 (es)	2014-09-24	2021-05-05	Univ Indiana Res & Tech Corp	Conjugados de incretina-insulina
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
PE20180158A1 (es)	2014-10-24	2018-01-18	Merck Sharp & Dohme	Coagonistas de los receptores de glucagon y de glp-1
MX381640B (es)	2014-10-29	2025-03-04	Zealand Pharma As	Metodos y compuestos agonistas de gip.
KR102418477B1 (ko) *	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
PE20230304A1 (es) *	2014-12-30	2023-02-13	Hanmi Pharm Ind Co Ltd	Derivados de glucagon como agentes hipoglucemicos y antiobesidad
AR103954A1 (es)	2015-03-18	2017-06-14	Zealand Pharma As	Análogos de amilina
ES2805743T3 (es)	2015-03-24	2021-02-15	Inst Nat Sante Rech Med	Método y composición farmacéutica para uso en el tratamiento de la diabetes
EP3283507B8 (en)	2015-04-16	2019-11-13	Zealand Pharma A/S	Acylated glucagon analogue
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
FI3322437T3 (fi)	2015-06-30	2024-02-20	Hanmi Pharmaceutical Co Ltd	Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
AU2016293619B2 (en)	2015-07-15	2021-02-25	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI622596B (zh)	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
WO2017074798A2 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Long-acting co-agonists of the glucagon and glp-1 receptors
EP3394091A4 (en)	2015-12-09	2019-12-18	Merck Sharp & Dohme Corp.	CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
MX395677B (es)	2015-12-23	2025-03-25	Amgen Inc	Proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1 para usarse en trastornos metabólicos
CN113456820B (zh)	2015-12-29	2023-09-08	派格生物医药(苏州)股份有限公司	包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
TWI877582B (zh)	2015-12-31	2025-03-21	南韓商韓美藥品股份有限公司	三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑
WO2017210099A1 (en) *	2016-06-02	2017-12-07	Indiana University Research And Technology Corporation	Glucagon-t3 conjugates
JP2019520336A (ja) *	2016-06-02	2019-07-18	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	水溶性で化学的に安定なグルカゴンペプチド
CN106084031B (zh) *	2016-06-02	2020-03-31	中国药科大学	一类glp-1r/gcgr双重激动剂在用于降糖和减肥药物中的运用
GB201611077D0 (en)	2016-06-24	2016-08-10	Arecor Ltd	Novel composition
SG11201811697SA (en)	2016-06-29	2019-01-30	Hanmi Pharmaceutical Co Ltd	Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
US9994591B2 (en)	2016-08-05	2018-06-12	Boehringer Ingelheim International Gmbh	Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
TW201832783A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
BR112019010624A2 (pt)	2016-12-09	2019-10-22	Zealand Pharma As	agonistas duplos de glp-1/glp-2 acilados e composição
JOP20190177A1 (ar)	2017-01-17	2019-07-16	Amgen Inc	طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
AU2018210174B2 (en)	2017-01-18	2022-04-07	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI791539B (zh)	2017-06-16	2023-02-11	丹麥商西蘭製藥公司	用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
BR112019024410A2 (pt)	2017-06-20	2020-07-14	Amgen Inc.	método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
AU2018288852B2 (en)	2017-06-21	2025-02-27	Amgen Inc.	Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
EP3700550A4 (en)	2017-09-25	2022-02-23	Merck Sharp & Dohme Corp.	LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
CN109836488B (zh) *	2017-11-24	2022-08-23	浙江道尔生物科技有限公司	一种治疗代谢疾病的胰高血糖素类似物
CN109836503B (zh) *	2017-11-24	2022-09-16	浙江道尔生物科技有限公司	一种治疗代谢疾病的多重活性蛋白
CN109836504B (zh) *	2017-11-24	2022-08-02	浙江道尔生物科技有限公司	一种治疗代谢疾病的多结构域活性蛋白
ES3002666T3 (en)	2018-01-03	2025-03-07	Mederis Diabetes Llc	Improved peptide pharmaceuticals for treatment of nash and other disorders
CA3087826A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
CR20200329A (es)	2018-02-02	2020-09-04	Boehringer Ingelheim Int	Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat)
JOP20200191A1 (ar)	2018-02-02	2020-07-29	Boehringer Ingelheim Int	مشتقات أوكسادايازولو بيريدين بها استبدال بسيكليل غير متجانسة للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
CN111630055B (zh)	2018-02-02	2023-07-14	勃林格殷格翰国际有限公司	用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
WO2019157268A1 (en)	2018-02-08	2019-08-15	Protagonist Therapeutics, Inc.	Conjugated hepcidin mimetics
WO2020014646A1 (en)	2018-07-12	2020-01-16	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3123979A1 (en)	2018-12-21	2020-06-25	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
CN111944055B (zh) *	2019-05-16	2022-08-02	浙江道尔生物科技有限公司	一种治疗代谢疾病的融合蛋白
MX2022001020A (es)	2019-07-29	2022-04-06	Univ Illinois	Composicion y metodo para promover la cicatrizacion de heridas.
CN114729022A (zh)	2019-09-03	2022-07-08	领导医疗有限公司	缀合的铁调素模拟物
WO2021070202A1 (en) *	2019-10-09	2021-04-15	Prasad Alaparthi Lakshmi	A method for preparing glp-1 analogue by solid-phase peptide synthesis
MX2022005661A (es)	2019-11-11	2022-09-07	Boehringer Ingelheim Int	Agonistas del receptor npy2.
EP3842449A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) *	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842060A1 (en) *	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled lactam co-agonists of the glucagon and glp-1 receptors
PH12022551750A1 (en)	2020-01-15	2023-11-13	Janssen Biotech Inc	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112022014011A2 (pt)	2020-01-15	2022-12-20	Janssen Biotech Inc	Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias
CN115515641B (zh) *	2020-04-29	2025-11-18	株式会社原真生物技术	新型蛋白质结合物及其非酒精性脂肪性肝炎、肥胖及糖尿病的预防或治疗用途
WO2021233882A1 (en)	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2021233884A1 (en)	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
BR112022025623A2 (pt)	2020-08-07	2023-03-07	Boehringer Ingelheim Int	Agonistas solúveis de receptores de npy2
TW202237167A (zh)	2020-11-20	2022-10-01	比利時商健生藥品公司	介白素-23受體之肽抑制劑組合物
CN117202924A (zh)	2020-12-07	2023-12-08	斯皮特弗尔制药有限责任公司	使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CA3215858A1 (en)	2021-04-27	2022-11-03	Zhenhuan ZHENG	Combination of bitter receptor agonist and gut-signaling compound
US20250320252A1 (en)	2021-06-09	2025-10-16	The Scripps Research Institute	Long-acting dual gip/glp-1 peptide conjugates and methods of use
WO2022262825A1 (zh) *	2021-06-18	2022-12-22	南京明德新药研发有限公司	含内酰胺桥的多肽化合物
GB202109087D0 (en)	2021-06-24	2021-08-11	Norwegian Univ Sci & Tech Ntnu	Therapeutic methods and devices
PE20240595A1 (es)	2021-07-14	2024-03-21	Janssen Biotech Inc	Inhibidores peptidicos lipidicos del receptor de iinterleucina-23
WO2023016346A1 (zh) *	2021-08-10	2023-02-16	南京明德新药研发有限公司	含内酰胺桥的多肽化合物
CN115536739B (zh) *	2022-07-04	2023-04-14	北京惠之衡生物科技有限公司	一种glp-1受体和gcg受体共激动多肽衍生物的制备方法
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275152A (en) *	1977-02-03	1981-06-23	Eastman Kodak Company	Hydrolysis of protein-bound cholesterol esters
PT83613B (en)	1985-10-28	1988-11-21	Lilly Co Eli	Process for the selective chemical removal of a protein amino-terminal residue
US5539084A (en)	1989-02-17	1996-07-23	Coselco Mimotopes Pty. Ltd.	Method for the use and synthesis of peptides
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
DE69129226T2 (de)	1990-01-24	1998-07-30	Douglas I. Woodside Calif. Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
CA2024855C (en)	1990-09-07	1997-12-09	Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee	Process and intermediates for producing glucagon
JPH04145099A (ja)	1990-10-05	1992-05-19	Sanwa Kagaku Kenkyusho Co Ltd	Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) *	1991-01-17	1996-04-23	Zymogenetics, Inc.	Glucagon antagonists
US5359030A (en) *	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) *	1993-12-29	1996-01-02	The Rockefeller University	Glucagon analogs with serine replacements
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
CA2243718A1 (en)	1996-02-06	1997-08-14	Eli Lilly And Company	Diabetes therapy
PT915910E (pt)	1996-06-05	2006-05-31	Roche Diagnostics Gmbh	Analogos de exendina, processos para a sua preparacao e medicamentos que os contem
IL128828A0 (en)	1996-09-09	2000-01-31	Zealand Pharmaceuticals As	Peptide prodrugs containing an alpha-hydroxy acid linker
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU5518798A (en)	1996-12-03	1998-06-29	Trustees Of Boston University	Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
CA2321026A1 (en)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) *	1998-09-02	2003-12-25	Renuka Pillutla	Isulin and IGF-1 receptor agonists and antagonists
AU6294899A (en)	1998-10-07	2000-04-26	Medical College Of Georgia Research Institute, Inc.	Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
ES2230912T3 (es)	1998-12-07	2005-05-01	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogo de glp-1.
AU3033500A (en)	1999-01-15	2000-08-01	Agouron Pharmaceuticals, Inc.	Non-peptide glp-1 agonists
GB0404124D0 (en)	2004-02-25	2004-03-31	Univ Ulster	Antagonists of GIP
ES2225107T3 (es)	1999-03-29	2005-03-16	Uutech Limited	Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes.
AU754770B2 (en)	1999-05-17	2002-11-21	Conjuchem Biotechnologies Inc.	Long lasting insulinotropic peptides
AU2001257278A1 (en)	2000-04-27	2001-11-07	Bionebraska, Inc.	Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en) *	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
WO2001096368A2 (en)	2000-06-14	2001-12-20	Cytovax Biotechnologies, Inc.	Use of coiled-coil structural scaffold to generate structure-specific peptides
US7084243B2 (en)	2000-06-16	2006-08-01	Eli Lilly And Company	Glucagon-like peptide-1 analogs
BR0113178A (pt)	2000-08-02	2004-04-06	Theratechnologies Inc	Peptìdeos biológicos modificados com potência aumentada
US20020045572A1 (en)	2000-08-15	2002-04-18	Cpd, Llc	Method of treating the syndrome of type 2 diabetes in humans
US6528520B2 (en)	2000-08-15	2003-03-04	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en)	2000-08-15	2001-07-17	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en)	2000-08-15	2005-01-25	Cpd, Llc	Method of treating the syndrome of lipodystrophy
EP1324779B1 (en) *	2000-09-29	2011-07-20	Schering Corporation	Pegylated interleukin-10
US7199217B2 (en)	2000-12-13	2007-04-03	Eli Lilly And Company	Amidated glucagon-like peptide-1
EP1411968B1 (en)	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
EP1572885A2 (en) *	2001-08-08	2005-09-14	Genzyme Corporation	Methods for treating diabetes and other blood sugar disorders
US7238663B2 (en) *	2001-08-28	2007-07-03	Eli Lilly And Company	Pre-mixes of GLP-1 and basal insulin
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
US7041646B2 (en)	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AR036711A1 (es) *	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US6864069B2 (en)	2001-10-05	2005-03-08	Bayer Pharmaceuticals Corporation	Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
GEP20063908B (en)	2001-10-18	2006-08-25	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005508360A (ja)	2001-10-19	2005-03-31	イーライ・リリー・アンド・カンパニー	Ｇｌｐ−１およびインスリンの二相混合物
WO2003059378A2 (en) *	2001-12-29	2003-07-24	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
MXPA04006679A (es)	2002-01-08	2004-11-10	Lilly Co Eli	Analogos extendidos de peptido-1 de tipo glucagon.
US20030232761A1 (en)	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
WO2003103572A2 (en)	2002-06-04	2003-12-18	Eli Lilly And Company	Modified glucagon-like peptide-1 analogs
WO2003103697A2 (en)	2002-06-11	2003-12-18	Cell Therapeutics Scandinavia Ab	Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
AU2003248676A1 (en)	2002-06-15	2003-12-31	Enteromed, Inc.	Treatment of non-alcoholic fatty liver disease
JP2006501820A (ja)	2002-09-06	2006-01-19	バイエル・フアーマシユーチカルズ・コーポレーシヨン	修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
WO2004067548A2 (en)	2003-01-31	2004-08-12	Theratechnologies Inc.	Chemically modified metabolites of regulatory peptides and methods of producing and using same
WO2004078777A2 (en)	2003-03-04	2004-09-16	Biorexis Pharmaceutical Corporation	Dipeptidyl-peptidase protected proteins
HRP20050683A2 (en)	2003-03-19	2006-07-31	Eli Lilly And Company	Polyethylene glycol linked glp-1 compounds
AU2004228793B2 (en)	2003-04-08	2009-10-08	Yeda Research And Development Co. Ltd.	Reversible pegylated drugs
CA2525574C (en)	2003-05-15	2015-06-30	Trustees Of Tufts College	Stable analogs of peptide and polypeptide therapeutics
MXPA05013048A (es)	2003-06-03	2006-03-02	Novo Nordisk As	Composiciones peptodicas farmaceuticas estabilizadas.
WO2004105790A1 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
MXPA05013565A (es)	2003-06-12	2006-03-09	Lilly Co Eli	Proteinas de fusion analogas al glp-1.
US20050124550A1 (en)	2003-06-18	2005-06-09	Peri Krishna G.	Compounds that modulate the glucagon response and uses thereof
MXPA06002941A (es)	2003-09-19	2006-05-31	Novo Nordisk As	Derivados de enlace a albumina de peptidos terapeuticos.
US7364875B2 (en) *	2003-10-30	2008-04-29	Cresent Innovations, Inc.	Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
JP2007537141A (ja)	2003-12-18	2007-12-20	ノボ　ノルディスク　アクティーゼルスカブ	新規なｇｌｐ−１化合物
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
US20080318837A1 (en) *	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7442682B2 (en)	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
EP2390264A1 (en)	2005-02-11	2011-11-30	Amylin Pharmaceuticals Inc.	GIP analog and hybrid polypeptides with selectable propperties
EP1863537A2 (en)	2005-03-18	2007-12-12	Novo Nordisk A/S	Dimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en)	2005-05-06	2006-11-16	Bayer Pharmaceuticals Corporation	Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
KR101011081B1 (ko)	2005-05-13	2011-01-25	일라이 릴리 앤드 캄파니	Ｐｅｇ화된 ｇｌｐ-1 화합물
SI1891105T1 (sl)	2005-06-13	2012-07-31	Imp Innovations Ltd	Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
EP2330124B1 (en)	2005-08-11	2015-02-25	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
AU2006289259A1 (en)	2005-09-08	2007-03-15	Uutech Limited	Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007028633A2 (en)	2005-09-08	2007-03-15	Uutech Limited	Treatment of diabetes related obesity
EP1959986B1 (en) *	2005-11-07	2014-07-23	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
EP1991574B1 (en)	2006-02-22	2016-10-12	Merck Sharp & Dohme Corp.	Oxyntomodulin derivatives
WO2007104786A1 (en)	2006-03-15	2007-09-20	Novo Nordisk A/S	Mixtures of amylin and insulin
US20090186817A1 (en)	2006-03-21	2009-07-23	Amylin Pharmaceuticals, Inc.	Peptide-peptidase inhibitor conjugates and methods of using same
EP2574624A1 (en)	2006-04-20	2013-04-03	Amgen Inc.	GLP-1 compounds
WO2008022015A2 (en)	2006-08-11	2008-02-21	Trustees Of Tufts College	Retro-inverso incretin analogues, and methods of use thereof
JP5399244B2 (ja)	2006-08-17	2014-01-29	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
EP2057189B1 (en)	2006-08-25	2013-03-06	Novo Nordisk A/S	Acylated exendin-4 compounds
AU2007292903B2 (en) *	2006-09-08	2012-03-29	Ambrx, Inc.	Modified human plasma polypeptide or Fc scaffolds and their uses
EP2102355B1 (en)	2006-12-14	2016-03-02	Bolder Biotechnology, Inc.	Long acting proteins and peptides and methods of making and using the same
WO2008086086A2 (en) *	2007-01-05	2008-07-17	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2111414B1 (en)	2007-02-15	2014-07-02	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
JP5385266B2 (ja)	2007-06-15	2014-01-08	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP5476304B2 (ja)	2007-09-05	2014-04-23	ノボ・ノルデイスク・エー／エス	グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
EP2190873B1 (en)	2007-09-05	2015-07-22	Novo Nordisk A/S	Truncated glp-1 derivatives and their therapeutical use
US20100256056A1 (en)	2007-09-07	2010-10-07	Zheng Xin Dong	Analogues of exendin-4 and exendin-3
EP2036923A1 (en)	2007-09-11	2009-03-18	Novo Nordisk A/S	Improved derivates of amylin
EP2200635A1 (en)	2007-09-11	2010-06-30	Novo Nordisk A/S	Mixture comprising an amylin peptide and a protracted insulin
EP2036539A1 (en)	2007-09-11	2009-03-18	Novo Nordisk A/S	Stable formulations of amylin and its analogues
MX2010004297A (es)	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Antagonistas de glucagon.
JP5771005B2 (ja)	2007-10-30	2015-08-26	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
CN101918027A (zh)	2007-11-02	2010-12-15	森托科尔奥索生物科技公司	半合成GLP-1肽-Fc融合构造、方法及其用途
EP2249853A4 (en) *	2008-01-30	2012-12-26	Univ Indiana Res & Tech Corp	ESTER BASED PEPTIDE PRODRUGS
EP2596805B1 (en)	2008-02-01	2021-10-27	Ascendis Pharma A/S	Prodrug comprising a drug-linker conjugate
AU2009274425B2 (en)	2008-06-17	2014-05-15	Indiana University Research And Technology Corporation	GIP-based mixed agonists for treatment of metabolic disorders and obesity
CA2728284C (en)	2008-06-17	2019-09-10	Richard D. Dimarchi	Glucagon/glp-1 receptor co-agonists
CN104447980A (zh) *	2008-06-17	2015-03-25	印第安纳大学研究及科技有限公司	在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
TWI489992B (zh)	2008-12-19	2015-07-01	印地安那大學研究及技術公司	醯胺系胰高血糖素超級家族之胜肽前驅藥物
WO2010080605A1 (en)	2008-12-19	2010-07-15	Indiana University Research And Technology Corporation	Dipeptide linked medicinal agents
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
CN102459325B (zh)	2009-06-16	2015-03-25	印第安纳大学科技研究有限公司	胃抑胜肽受体活化的胰高血糖素化合物
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Axentomodulin polypeptide
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
CA2788304A1 (en)	2010-01-27	2011-08-04	Indiana University Research And Technology Corporation	Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (es)	2010-03-26	2012-04-18	Lilly Co Eli	Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
RU2604067C2 (ru)	2010-05-13	2016-12-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
EP2588126A4 (en)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
WO2011163473A1 (en)	2010-06-25	2011-12-29	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers

2008
- 2008-02-13 EP EP20080729769 patent/EP2111414B1/en not_active Revoked
- 2008-02-13 CA CA 2677932 patent/CA2677932A1/en not_active Abandoned
- 2008-02-13 KR KR20097018548A patent/KR20090119876A/ko not_active Ceased
- 2008-02-13 NZ NZ578948A patent/NZ578948A/en not_active IP Right Cessation
- 2008-02-13 MX MX2009008241A patent/MX2009008241A/es active IP Right Grant
- 2008-02-13 EA EA200901108A patent/EA017849B1/ru not_active IP Right Cessation
- 2008-02-13 CN CN200880012086.2A patent/CN101790538B/zh not_active Expired - Fee Related
- 2008-02-13 WO PCT/US2008/053857 patent/WO2008101017A2/en not_active Ceased
- 2008-02-13 AU AU2008216265A patent/AU2008216265B2/en not_active Ceased
- 2008-02-13 GE GEAP200811468A patent/GEP20135944B/en unknown
- 2008-02-13 BR BRPI0807728-2A patent/BRPI0807728A2/pt not_active IP Right Cessation
- 2008-02-13 EP EP20110196006 patent/EP2487184A1/en not_active Withdrawn
- 2008-02-13 KR KR1020157026403A patent/KR20150116465A/ko not_active Ceased
- 2008-02-13 US US12/527,140 patent/US8454971B2/en not_active Expired - Fee Related
- 2008-02-13 JP JP2009549703A patent/JP6017754B2/ja not_active Expired - Fee Related
- 2008-02-14 TW TW097105251A patent/TWI547499B/zh active
- 2008-02-14 PA PA8769301A patent/PA8769301A1/es unknown
- 2008-02-14 AR ARP080100632 patent/AR065349A1/es not_active Application Discontinuation
- 2008-02-14 CL CL2008000479A patent/CL2008000479A1/es unknown
- 2008-02-14 PE PE2008000317A patent/PE20090108A1/es not_active Application Discontinuation
- 2008-02-14 PE PE2013000081A patent/PE20140159A1/es not_active Application Discontinuation
2009
- 2009-07-30 TN TNP2009000313A patent/TN2009000313A1/fr unknown
- 2009-07-30 DO DO2009000194A patent/DOP2009000194A/es unknown
- 2009-08-06 ZA ZA2009/05521A patent/ZA200905521B/en unknown
- 2009-08-13 GT GT200900229A patent/GT200900229A/es unknown
- 2009-08-13 HN HN2009001593A patent/HN2009001593A/es unknown
- 2009-08-13 IL IL200396A patent/IL200396A/en active IP Right Grant
- 2009-08-13 NI NI200900158A patent/NI200900158A/es unknown
- 2009-09-07 MA MA32206A patent/MA31242B1/fr unknown
- 2009-09-10 EC ECSP099622 patent/ECSP099622A/es unknown
- 2009-09-14 CR CR11028A patent/CR11028A/es unknown
2011
- 2011-04-14 AR ARP110101281 patent/AR080904A2/es not_active Application Discontinuation
2013
- 2013-01-09 US US13/737,232 patent/US8900593B2/en not_active Expired - Fee Related
2014
- 2014-03-05 JP JP2014043047A patent/JP2014141500A/ja active Pending
- 2014-11-07 US US14/535,853 patent/US9447162B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL200396A0 (en)	2010-04-29
EA017849B1 (ru)	2013-03-29
AU2008216265B2 (en)	2014-04-03
US20100190701A1 (en)	2010-07-29
ECSP099622A (es)	2009-10-30
AU2008216265A1 (en)	2008-08-21
CN101790538A (zh)	2010-07-28
CR11028A (es)	2009-10-29
GT200900229A (es)	2011-01-21
KR20150116465A (ko)	2015-10-15
GEP20135944B (en)	2013-10-25
NZ578948A (en)	2012-03-30
CA2677932A1 (en)	2008-08-21
AR065349A1 (es)	2009-06-03
BRPI0807728A2 (pt)	2012-04-17
CN101790538B (zh)	2014-07-30
NI200900158A (es)	2010-09-07
JP6017754B2 (ja)	2016-11-02
US8454971B2 (en)	2013-06-04
KR20090119876A (ko)	2009-11-20
WO2008101017A2 (en)	2008-08-21
EP2487184A1 (en)	2012-08-15
EP2111414B1 (en)	2014-07-02
IL200396A (en)	2016-02-29
EA200901108A1 (ru)	2010-02-26
AR080904A2 (es)	2012-05-16
HK1135993A1 (en)	2010-06-18
US20150126440A1 (en)	2015-05-07
HN2009001593A (es)	2012-08-13
JP2014141500A (ja)	2014-08-07
MX2009008241A (es)	2009-10-08
MA31242B1 (fr)	2010-03-01
EP2111414A2 (en)	2009-10-28
US8900593B2 (en)	2014-12-02
DOP2009000194A (es)	2010-06-30
PE20140159A1 (es)	2014-02-08
TN2009000313A1 (en)	2010-12-31
PE20090108A1 (es)	2009-02-15
TWI547499B (zh)	2016-09-01
WO2008101017A3 (en)	2008-12-18
US20130203660A1 (en)	2013-08-08
PA8769301A1 (es)	2008-12-18
TW200848423A (en)	2008-12-16
JP2011511753A (ja)	2011-04-14
US9447162B2 (en)	2016-09-20
ZA200905521B (en)	2011-10-26

Publication	Publication Date	Title
CL2008000479A1 (es)	2008-08-22	Peptido de glucagon no nativo; composicion farmaceutica que lo comprende; y metodo para tratar la hipoglucemia y diabetes.
CL2008001334A1 (es)	2008-09-22	Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CL2009001424A1 (es)	2010-04-30	Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
CL2007003212A1 (es)	2008-06-27	Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
BRPI0717657A2 (pt)	2013-12-24	Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii
CL2013003454A1 (es)	2014-06-13	Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
CL2008000067A1 (es)	2008-05-16	Compuestos derivados de espirocromanona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, higado graso, hiperlipemia, obesidad, diabetes, bulimia, neoplasma maligno o enfermedades infecciosas.
CL2007003176A1 (es)	2008-07-25	Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
CL2007002834A1 (es)	2008-05-16	Compuestos derivados de pirazina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos relacionados con inflamacion, tales como artritis, intestino inflamado, alergia,
CL2007002021A1 (es)	2008-02-08	Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.
CL2014002100A1 (es)	2015-10-23	Compuestos biciclicos nitrogenados; composicion farmaceutica que los comprende y uso para el tratamiento de la atrofia muscular espinal.
BRPI0817473A2 (pt)	2017-05-16	plataforma de aplicativo para executar aplicativos
CL2013001410A1 (es)	2014-03-07	Variante polipeptidica de fgf21; multimero que la comprende; composicion farmaceutica que la comprende; y su uso para tratar uno o mas trastornos asociados a fgf21.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2008000046A1 (es)	2008-05-09	Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione
CL2008001002A1 (es)	2008-10-17	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0922619A2 (pt)	2016-09-13	compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento
CL2008001003A1 (es)	2008-10-17	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2008000029A1 (es)	2008-04-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003423A1 (es)	2008-07-18	Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0809661A2 (pt)	2014-10-14	Composição farmacêutica estabilizada contendo pregabalina
CL2008000585A1 (es)	2008-08-29	Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds.
BRPI1009781A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos